AstraZeneca (AZN +0.3%) says results from its PLATO study of a greater reduction in thrombotic...


AstraZeneca (AZN +0.3%) says results from its PLATO study of a greater reduction in thrombotic cardiovascular events with Brilinta tablets plus aspirin compared to clopidogrel plus aspirin were consistent regardless of age. The data is now published in the September issue of Circulation: Cardiovascular Quality and Outcomes, and were presented at the American College of Cardiology.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs